1/15/2021 6:58:44 AM
Five Prime Therapeutics Presents Phase 2 FIGHT Trial Results Of FGFR2b
11/12/2020 10:15:51 PM
Five Prime Therapeutics Announces Pricing Of Underwritten Public Offering Of 7.20 Mln Shares At $21.00/shr
11/11/2020 4:04:00 PM
Five Prime Announces Proposed Public Offering Of Common Stock
4/14/2020 9:06:44 AM
Five Prime Therapeutics Names Thomas Civik As President And CEO
3/13/2020 9:28:28 AM
Five Prime Therapeutics Announces Publication Of The Phase 1 Bemarituzumab Study
12/26/2019 4:19:24 PM
Five Prime Therapeutics Announces Resignation Of Lewis Williams From Board Of Directors
6/24/2019 4:21:54 PM
Five Prime Therapeutics Appoints Lori Lyons-Williams To Its Board Of Directors
5/10/2019 8:42:01 AM
Wedbush Is Cutting Five Prime Therapeutics (FPRX) FY19 Rev. Estimate To 23.3 M From 24.0 M